This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Erik A. Lippa, MD, PhD; Henry Aasved, MD; P. Juhani Airaksinen, MD; Albert Alm, MD; Torstein Bertelsen, MD; Berit Calissendorff, MD; Ole Dithmer, MD; Lars-Olaf Eriksson, PhD; Laila Gustad, MD; Gunnar Høvding, MD; Eva Mönestam, MD; Erik Krogh, MD; Denise Deasy, MS; Deborah Panebianco, MS; Anja Tuulonen, MD

Arch Ophthalmol. 1991;109(1):46-49.

Abstract
• The multiple-dose, dose-response curve of MK-927 was studied in a fivecenter, double-masked, randomized, placebo-controlled, parallel study of 2%, 1%, and 0.5% MK-927 in 76 patients with bilateral primary open angle glaucoma or ocular hypertension and intraocular pressure greater than 24 mm Hg following washout of ocular hypotensive medications. Patients received doses at 8 AM and 8 PM for 14 days, and parallel 12-hour intraocular pressure curves were performed prestudy and on day 14, with 4-hour curves on days 1 and 4. There was a significant dose-response relationship, with 0.5% MK-927 twice daily being a minimal-effect dose. Both 1% and 2% MK-927 were active through 12 hours postdose, and peak mean percent decrease in pressure at 2 hours postdose was 18.6% and 20.6%, respectively.

Author Affiliations
From the Departments of Ophthalmology, Universities of Bergen (Norway) (Drs Aasved, Bertelsen, and Høvding), Oulu (Finland) (Drs Airaksinen and Tuulonen), Umea (Sweden) (Drs Alm and Mönestam), Stockholm (Sweden) (Drs Calissendorff and Gustad), Copenhagen (Denmark) (Drs Dithmer and Krogh), and the Departments of Clinical Research (Dr Lippa and Ms Deasy), Clinical Pharmacology (Dr Eriksson), and Biostatistics (Ms Panebianco), Merck Sharp & Dohme Research Laboratory, West Point, Pa.

Footnotes
Accepted for publication September 13, 1990.

Poster presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, April 30, 1989.

Reprint requests to Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486 (Dr Lippa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma
Schmidt et al.
Br J Ophthalmol 1998;82:758-762.
ABSTRACT | FULL TEXT  

Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT  

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor
Lippa et al.
Arch Ophthalmol 1992;110:495-499.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT